Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis

封面

如何引用文章

全文:

详细

Clinical observations of three patients aged 26, 43 and 37 years with severe psoriasis and psoriatic arthritis are presented. Clinical examples show the experience of effective treatment of patients with psoriasis and psoriatic arthritis using anti-cytokine therapy with an interleukin-17 inhibitor, initiated when the disease progresses. The clinical picture of the presented observations was characterized by an aggressive course of the skin and articular process, torpidity to basic therapy, despite the young age of the patients. It has been shown that the early termination of the progression of the inflammatory process in psoriasis with the use of genetically engineered biological therapy with secukinumab leads to a decrease in symptoms, both on the part of the skin and manifestations of the disease on the part of the musculoskeletal system. The high efficacy and safety of the drug allow complete control of the disease and improve the quality of life in patients suffering from severe forms of dermatosis.

作者简介

Julia Kovaleva

Altay State Medical University

编辑信件的主要联系方式.
Email: julia_jsk@mail.ru
ORCID iD: 0000-0002-4401-3722

MD, Dr. Sci. (Med.), Assistant Professor
俄罗斯联邦, Barnaul

Igor Kazantsev

Regional Dermatovenereologic Dispensary Altai Territory

Email: priemnaya.kkvd@mail.ru

Dermatovenereologist

俄罗斯联邦, Barnaul

Annetta Aibazova

Regional Dermatovenereologic Dispensary Altai Territory

Email: annetta.aybazova@mail.ru

Dermatovenereologist

俄罗斯联邦, Barnaul

Ekaterina Ovchinnikova

Regional Dermatovenereologic Dispensary Altai Territory

Email: docovchinnikova@mail.ru

Dermatovenereologist

俄罗斯联邦, Barnaul

Anastasia Garina

Regional Dermatovenereologic Dispensary Altai Territory

Email: vika.garina.1988@mail.ru

Dermatovenereologist

俄罗斯联邦, Barnaul

Anastasia Shabaldina

Regional Dermatovenereologic Dispensary Altai Territory

Email: nastya_190589@mail.ru

Dermatovenereologist

俄罗斯联邦, Barnaul

参考

  1. Кубанов А.А., Карамова А.Э., Притуло О.А., Аршинский М.И., Знаменская Л.Ф., Чикин В.В. и др. Псориаз: клинические рекомендации. М.; 2023. [Kubanov AA, Karamova AE, Pritulo OA, Arshinskij MI, Znamenskaja LF, Chikin V.V. et al. Psoriaz: Klinicheskie rekomendacii. Moscow; 2023. (In Russ.)] URL: https://cr.minzdrav.gov.ru/schema/234_2
  2. Bulat V, Šitum M, Delaš Aždajić M, Lovrić I, Dediol I. Study on the Impact of Psoriasis on Quality of Life: Psychological, Social and Financial Implications. Psychiatr Danub. 2020;32(Suppl 4):553–561.
  3. Круглова Л.С., Моисеев С.В. Блокада интерлейкина-17 — новые горизонты эффективности и безопасности в лечении псориаза. Клиническая фармакология и терапия. 2017;26(2):5–12. [Kruglova LS, Moiseev SV. Interleukin-17 blockade — new horizons of efficacy and safety in the treatment of psoriasis. Klinicheskaya farmakologiya i terapiya = Clinical pharmacology and therapy. 2017;26(2):5–12. (In Russ.)]
  4. Коротаева Т.В., Корсакова Ю.Л. Псориатический артрит: классификация, клиническая картина, диагностика, лечение. Научно-практическая ревматология. 2018;56(1):60–69. [Korotayeva TV, Korsakova YuL. Psoriatic arthritis: classification, clinical picture, diagnosis, treatment. Nauchno-prakticheskaya revmatologiya, Nasonova Research Institute of Rheumatology. 2018;56(1):60–69. (In Russ.)] doi: 10.14412/1995-4484-2018-60-69
  5. Jankowiak B, Kowalewska B, Krajewska-Kułak E, Kowalczuk K, Khvorik DF. The Sense of Stigmatization in Patients with Plaque Psoriasis. Dermatology. 2021;237(4):611–617. doi: 10.1159/000510654
  6. Кубанов А.А., Богданова Е.В. Эпидемиология псориаза в Российской Федерации (по данным регистра). Вестник дерматологии и венерологии. 2022;98(2):33–41. [Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the register. Vestnik Dermatologii i Venerologii. 2022;98(2):33–41. (In Russ.)] doi: 10.25208/vdv1268
  7. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–265.е19. doi: 10.1016/j.jaad.2018.06.027
  8. Torti DC, Feldman SR. Interleukin-12, interleukin-23, and psoriasis: current prospects. J Am Acad Dermatol. 2007;57(6):1059–1068. doi: 10.1016/j.jaad.2007.07.016
  9. Олисова О.Ю., Гаранян Л.Г. Эпидемиология, этиопатогенез и коморбидность при псориазе — новые факты. Российский журнал кожных и венерических болезней. 2017;20(4):214–219. [Olisova OYu, Garanyan LG. Epidemiology, etiopathogenesis and comorbidity in psoriasis — new facts. Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney = Russian journal of skin and venereal diseases. 2017;20(4):214–219. (In Russ.)] doi: 10.18821/1560-9588-2017-20-4-214-219
  10. Rouvier E, Luciani MF, Mattéi MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol. 1993;150(12):5445–5456.
  11. Van den Berg WB, McInnes IB. Th17 cells and IL-17 a-focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum. 2013;43(2):158–170. doi: 10.1016/j.semarthrit.2013.04.006
  12. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361(9):888–898. doi: 10.1056/NEJMra0707449
  13. Frleta M, Siebert S, McInnes IB. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibili- ties of treatment. Curr Rheumatol Rep. 2014;16(4):414. doi: 10.1007/s11926-014-0414-y
  14. Johansen C, Usher PA, Kjellerup RB, et al. Characterization of the interleukin-17 isoform and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319–324. doi: 10.1111/j.1365- 2133.2008.08902.x
  15. Коротаева Т.В. Перспективы применения ингибиторов интерлейкина-17 — нового класса препаратов для таргетной терапии псориатического артрита. Научно-практическая ревматология. 2016;54(3):346–351. [Korotaeva TV. Prospects for using interleukin-17 inhibitors, a new class of drugs for targeted therapy of psoriatic arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(3):346–351. (In Russ.)] doi: 10.14412/1995-4484-2016-436-351
  16. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol. 2010;6(12):704–714. doi: 10.1038/nrrheum.2010.157
  17. Зильберберг Н.В., Кащеева Я.В., Кохан М.М. Опыт применения препарата секукинумаб в терапии больных псориазом. Лечащий врач. 2021;10:41–45. [Zilberberg NV, Kascheeva YaV, Kokhan MM. Experience of using secukinumab in the treatment of patients with psoriasis. Lechaschi Vrach. 2021;10:41–45. (In Russ.)] doi: 10.51793/OS.2021.24.10.007
  18. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis. Results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi: 10.1056/NEJMoa1314258
  19. Thaçi D, Blauvelt A, Reich K., Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi: 10.1016/j.jaad.2015.05.013

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Before starting therapy

下载 (1MB)
索引源数据
3. Fig. 2. 12 weeks after starting therapy with secukinumab

下载 (1MB)
索引源数据
4. Fig. 3. Before starting therapy

下载 (1MB)
索引源数据
5. Fig. 4. 12 weeks after starting therapy with secukinumab

下载 (1MB)
索引源数据
6. Fig. 5. Before starting therapy

下载 (1MB)
索引源数据
7. Fig. 6. 10 weeks after starting therapy with secukinumab

下载 (765KB)
索引源数据

版权所有 © Kovaleva J.S., Kazantsev I.V., Aibazova A.A., Ovchinnikova E.O., Garina A.A., Shabaldina A.P., 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。
##common.cookie##